Chemopotential Features of Annona Muricata Leaves for Colorectal Neoplasm by Abdullah, M. (Murdani)
Volume 17, Number 3, December  2016 153
EDITORIAL
Chemopotential Features of Annona muricata 
Leaves for Colorectal Neoplasm
Murdani Abdullah
Division of Gastroenterology, Department of Internal Medicine, Universitas 
Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
Colorectal cancer was an emerging disease in 
the world with increasing prevalence over the year. 
According to the recent data, colorectal cancer was 
ranked second in males and third in female from 
all prevalence of cancer worldwide.1 Incidence of 
colorectal cancer in Indonesia is 17.2 per 100,000 
population with high mortality rate 12.9 per 100,000 
population.2 The increasing trend is need to be balanced 
with appropriate and ef¿cacious treatment and may 
need any adjuvant to the available treatment such as 
surgery, radiotherapy or chemotherapy. 
Indonesia is one of the tropical country with 
wide variety of biodiversity especially of herbal and 
natural compound.3 Herbal or traditional medicine was 
commonly used by the native Indonesian and believed as 
the traditional drug in rural as well as urban areas.4 Many 
studies of the natural compound have been conducted and 
have scienti¿cally potential ef¿cacy for medical uses. 
However, the study of this traditional material was limited 
and there were many of the natural compound that may 
be scienti¿cally bene¿t but have not been studied yet. 
Annona muricata (A. muricata) or soursop leaves 
was one of the natural resources that commonly used 
for traditional treatment. In addition, several studies of 
A. muricata suggested that the leaves of this compound 
had antibacterial, antiproliferative, antidiabetic, anti-
inÀammatory, antio[idant and other bene¿cial effects.5
Previous in vitro study from Indrawati et al 
demonstrated the potential chemotherapeutic effects. 
(thanol-soluble fraction of water e[tract of A. muricata 
(6)AM e[tract had cytoto[icity effects on D/D-1 
and COLO-205 which were colorectal cancer cell lines. 
The inhibitory concentration (IC50) of ESFAM was 
found lower than 5-Àuorouracil as positive control and 
placebo as negative control (20.59 μg/mL vs 277.7 μg/
mL and 654.9 μg/mL, respectively). Ex vivo e[periment 
also demonstrated that subjects’ serum could stimulate 
the activities of caspase-8 and caspase-9 on DLD-1 
cell lines. Caspase-8 and caspase-9 known as a marker 
of cancer apoptotic cycle.6 Abdullah et al also found 
that A. muricata has potential pro-apoptotic and anti-
proliferative by enhancing the e[pression of caspase-3 
on COLO-205 colorectal cancer cell line and down-
regulate CO;-2 e[pression on HT-29 colorectal cancer 
cell line.7,8
In vivo study from Moghadamtousi et al showed 
ethyl acetate e[tract of A. muricata leaves showed 
down-regulation of proliferating cell nuclear antigen, 
a marker of cell proliferation, and also Bcl-2. A. 
muricata also up-regulated Ba[ protein which was 
a pro-apoptotic that mediates the leakage of pro-
apoptotic factors including cytochrome c, Ca2+, and 
Smac/DIABLO.9
Indrawati et al then continued their study earlier 
and reviewed the safety pro¿le of one of the natural 
sources that may have potential effects on various 
disease treatment especially in colorectal cancer. 
Indrawati et al using the e[tract of A. muricata or 
soursop leaves and fractionated using ethanol to 
produce the ethanol-soluble fraction of water e[tract 
(ESFAM). This ESFAM contains 0.36% acetogenin, in 
which was the active compound that may has bene¿t 
for chemotherapy effect.10,11
This study is considered as Phase I clinical trial 
of A. muricata e[tract with 30 patients of colorectal 
cancer patients with previous complete resection of 
the primary tumour was included in the trial. Subjects 
randomly allocated in either supplementation of 300 
mg ESFAM or maltose as placebo in the form of 
capsule and administered after breakfast for as long 
as 8 weeks with mean 56 days taking the supplements. 
Indrawati et al found that A. muricata e[tract as 
the form of 300 mg ESFAM capsule was considered 
safe in administration in human subjects. No statistical 
signi¿cance was observed in the chemical marker 
such as hepatic function, kidney function, and 
haematological parameter after the prescription of the 
e[tract. Only 6.7% complained intolerant side effects. 
However, the authors did not mention the side effects 
occurred in the subjects.Presumably, the side effects 
may be harmless and suggested acceptable for patients 
taking the supplements. 
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This ¿nding could escalate further studies using 
the e[tract of Annona muricata leaves especially in 
colorectal cancer treatment. There may be bene¿t 
of this compound for its chemopotential effects in 
colorectal cancer.
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